Trials / Completed
CompletedNCT00674687
A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing
A Randomized Double-Blind, Placebo-Controlled, Crossover Study To Assess The Reproducibility And The Effect Of Gabapentin On Quantitative Sensory Testing In Neuropathic Pain Patients
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the reproducibility and the effect of gabapentin on quantitative sensory testing assessments in neuropathic pain subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 2-weeks placebo then gabapentin | Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week |
| DRUG | 1-week placebo then gabapentin | Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks |
Timeline
- Start date
- 2004-07-01
- Completion
- 2006-06-01
- First posted
- 2008-05-08
- Last updated
- 2021-02-02
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00674687. Inclusion in this directory is not an endorsement.